Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) Chief Legal Officer John McEvoy speaks to Thomas Warner from Proactive London about how he intends to carry out his new role, having joined Poolbeg on January 1st.
McEvoy details his transition from commercial-stage pharmaceutical company Amryt Pharma, saying that he was drawn to Poolbeg's potential for growth and innovation. His decision was influenced by previous encounters with Poolbeg's leadership team, notably Chairman Cathal Friel, and the company's promising pipeline, including its POLB 001 oncology asset.
McEvoy's tenure at Amryt was marked by significant accomplishments, including a $1.5 billion valuation and his recognition as Life Sciences Lawyer of the Year in 2023. He says his experience in guiding a high-growth, NASDAQ-listed company and expertise in multiple legal jurisdictions played a pivotal role in his success.
At Poolbeg, McEvoy aims to leverage his diverse legal background and strategic insight to drive the company's growth. He emphasises the importance of a holistic approach as a Chief Legal Officer, contributing not just legal expertise but also strategic guidance and leadership across the organisation.
McEvoy's focus will be on developing Poolbeg's intellectual property portfolio and exploring market opportunities for the company's assets, with an eye on near-term revenue generation and pipeline expansion.
